Chong Kun Dang Receives Approval for COVID-19 Treatment Clinical Trial Plan in Mexico

[Asia Economy Reporter Choi Dae-yeol] Chong Kun Dang announced on the 25th that it has received approval for Phase 2 clinical trials of Napabeltan, a COVID-19 treatment under development, from the Mexican pharmaceutical regulatory authority.

The company decided to develop the COVID-19 treatment in collaboration with the Salvador Zubir?n National Institute of Medical Sciences and Nutrition, one of the designated COVID-19 treatment hospitals under the local National Institutes of Health. Napabeltan contains Nafamostat as its main ingredient, which was identified as a potential COVID-19 treatment through drug repositioning research conducted by the Korea Pasteur Institute.

The local institute plans to administer the drug for ten days to 118 patients with moderate to severe pneumonia caused by COVID-19, depending on the patients' condition, to verify efficacy and safety. The company plans to apply for emergency approval in South Korea if the global clinical trials, conducted concurrently with the recently approved Phase 2 trial in Russia, succeed. In South Korea, the Phase 2 clinical trial plan has been approved and patient recruitment is underway, while in Russia, the trial is ongoing at 12 institutions.

This content was produced with the assistance of AI translation services.